Log In
Print
BCIQ
Print
Print this Print this
 

Tysabri, natalizumab

Also known as: AN100226 (formerly Antegren)

  Manage Alerts
Collapse Summary General Information
Company Biogen Inc.
DescriptionHumanized mAb against integrin alpha(4)
Molecular Target Integrin alpha(4) (VLA-4 ) (CD49D)
Mechanism of ActionBinds integrin alpha(4); Antibody
Therapeutic ModalityBiologic: Antibody

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

4

$20,350.0M

$6,443.8M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today